Clinical interest in semaglutide-induced loss of lean mass is increasing, which is particularly relevant in a post-MBS population likely to experience surgery-induced loss of lean mass
Link Wilding JPH, Batterham RL, Calanna S, et al
The two medications are similar in the following ways: Lower blood sugar and A1c levels Both Ozempic and Mounjaro have been proven to lower blood sugar and A1c levels
PAP also excludes Medicare beneficiaries, and you should verify the current rules at novocare.com/diabetes/help-with-costs/pap.html before relying on it
Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with MOUNJARO [see Warnings and Precautions (5.4)]
This question concerns many patients considering or currently taking this dual GIP/GLP-1 receptor agonist for type 2 diabetes or weight management